AMPK–p62 Feedback Amplifies Antioxidant Defense

How cancer cells coordinate energy conservation with antioxidant defense under nutrient limitation remains an important question in tumor biology. In their 2024 study in Autophagy, Eun-Ji Choi and colleagues describe a double-positive feedback loop between AMP-activated protein kinase (AMPK) and SQSTM1/p62. Their results connect lysosomal stress signaling to the simultaneous activation of AMPK and NFE2L2/NRF2, offering a mechanistic account of how stressed cells may reinforce survival programs.

The work also places MAP3K7/TAK1 within this response: ROS and pH-dependent lysosomal calcium release activate TAK1, which contributes to p62 phosphorylation. This makes the study relevant to researchers considering TAK1 as one component of stress adaptation, but it is not a study of a TAK1 inhibitor or a test of inhibitor efficacy.

Study Background and Research Question

In tumor microenvironments, nutrient depletion and reactive oxygen species (ROS) can occur together. Limited glucose metabolism can reduce the supply of metabolites needed to maintain redox balance, while oxidative damage to mitochondrial respiration can further compromise ATP production. The STK11/LKB1–AMPK pathway helps cells respond to energy stress by adjusting energy use and production. In parallel, KEAP1 normally restrains NRF2, a transcription factor that regulates antioxidant responses.

The authors focused on the relationship between these pathways. This question has particular relevance to non-small cell lung cancer (NSCLC), where co-occurring alterations in STK11/LKB1 and KEAP1 are associated with changes in metabolic and antioxidant signaling. The study asked how metabolic stress affects p62 and whether p62 links AMPK signaling with NRF2 activation. It further investigated the lysosomal and phosphorylation events that might connect stress sensing to this coordinated response (Choi et al.).

Key Innovation from the Reference Study

The central advance is the proposed two-way relationship between AMPK and p62, rather than a one-directional pathway in which AMPK simply responds to low energy. Under metabolic stress, AMPK activity contributes to increased p62 expression and phosphorylation; p62, in turn, supports AMPK activation. This feedback structure provides a plausible way for an initially transient stress signal to be amplified and sustained.

The authors also distinguish two downstream functions of p62. It promotes NRF2 activation by supporting autophagic degradation of KEAP1, thereby reducing a restraint on NRF2. Separately, p62 helps facilitate formation of the AXIN–STK11–AMPK complex at the lysosomal membrane. The model therefore connects p62 to both antioxidant transcription and energy-stress signaling, rather than treating these as independent responses. The study reports that phosphorylation at p62 S24 and S226 is important for this dual activity (reference study).

Methods and Experimental Design Insights

The experimental logic combines metabolic stress with pathway-level perturbations to trace the proposed sequence from lysosomal conditions to kinase signaling and antioxidant regulation. The study examines low-nutrient stress, p62 expression and phosphorylation, AMPK and NRF2 activation, and the roles of lysosomal function and pH. It also tests mechanisms involving TFEB/TFE3, PP2A, TAK1, and lysosomal calcium release. This layered design is useful because changes in NRF2 or AMPK alone would not establish how the two outputs are coordinated.

A notable element is the use of lactic acid as a counter-condition. The authors report that protons supplied by lactic acid abrogated effects induced by metabolic stress. This supports a role for lysosomal deacidification and pH-sensitive processes in the pathway, while also illustrating why metabolic stress should not be modeled as nutrient deprivation alone: pH and the surrounding metabolic environment can modify the cellular response.

Protocol Parameters

• Stress condition: Use a low-nutrient or low-glucose condition to investigate metabolic stress, and compare it with an appropriate nutrient-replete control. The study associates low glucose metabolism with lysosomal deacidification.
• pH-related comparison: Include a proton or lactic-acid counter-condition when testing whether stress-associated responses depend on lysosomal pH. The reference reports abrogation of metabolic-stress effects by lactic-acid-derived protons; establish the dose and exposure window for the chosen cell system rather than assuming a transferable setting.
• Pathway readouts: Assess p62 abundance and phosphorylation alongside AMPK activity, NRF2 signaling, and KEAP1 status. Measuring only one downstream output would not test the proposed dual activation.
• Mechanistic perturbation: Where suitable, compare wild-type p62 with S24/S226 phosphorylation-site variants and test lysosomal, phosphatase, or kinase contributions. These are experimental-design suggestions based on the mechanisms reported, not a substitute for the paper’s full methods or a universal protocol.
• Interpretation control: Confirm that a perturbation changes the intended lysosomal or signaling feature, and distinguish pathway association from direct causation using orthogonal genetic or pharmacological approaches.

Core Findings and Why They Matter

First, metabolic stress increased p62 expression and phosphorylation, and p62 was required for robust activation of both AMPK and NRF2. The two outputs arise through distinct but convergent mechanisms: p62 promotes KEAP1 degradation through autophagy to support NRF2, and it facilitates assembly of the AXIN–STK11–AMPK complex at lysosomes. This provides a cellular mechanism for coupling redox defense with energy adaptation rather than activating either response in isolation (Choi et al.).

Second, AMPK is not merely downstream of p62. The study reports that STK11–AMPK activity is also needed for stress-induced p62 expression and phosphorylation. This reciprocal dependence is the basis of the proposed positive-feedback loop. For researchers, it means that p62 abundance, p62 phosphorylation, and AMPK activity should be interpreted as potentially interdependent variables when analyzing stressed cells.

Third, the authors connect p62 expression to lysosomal pH regulation. Low glucose metabolism and AMPK-dependent proton reduction are associated with lysosomal deacidification. The resulting signaling involves PP2A-dependent dephosphorylation of TFEB and TFE3, transcription factors that contribute to increased p62 expression. In a parallel branch, ROS and pH-dependent release of lysosomal calcium activate TAK1, which increases p62 phosphorylation. The reported importance of S24 and S226 phosphorylation places these residues within the functional link between p62 and the dual AMPK–NRF2 response.

Together, these results offer an integrated model: metabolic stress changes lysosomal conditions, which support increased p62 expression and phosphorylation; p62 then reinforces AMPK and NRF2 signaling, while AMPK feeds back to maintain p62. Such reinforcement could help explain how tumor cells sustain antioxidant and metabolic adaptation. The authors suggest that this framework may help interpret co-occurring STK11 and KEAP1 alterations in lung cancer, but it does not by itself establish clinical benefit or predict response to a specific therapy.

Comparison with Existing Internal Articles

The internal overview “AMPK–SQSTM1 Feedback Loop Dual-Activates Antioxidant Defenses” covers the same central feedback model. The reference paper provides the primary evidence for the lysosomal, KEAP1, and phosphorylation mechanisms summarized here; the overview is useful as a companion orientation, not as an independent validation of those findings.

By contrast, the internal guide to applied TAK1 inhibition in inflammation models addresses a different experimental context. Its focus is pharmacological dissection of inflammatory TAK1 signaling, whereas Choi and colleagues examine TAK1 as part of a lysosome-linked metabolic-stress response. The overlap is the kinase, not the biological claim or experimental outcome.

Limitations and Transferability

The findings support a mechanistic model in the experimental systems studied, but additional work is needed to determine how broadly it applies across tumor types, nutrient environments, and genetic backgrounds. The supplied study summary does not establish that every cancer cell with STK11 or KEAP1 alterations will show the same dependence on p62, nor does it demonstrate that the feedback loop determines clinical outcomes. Because p62 has multiple cellular roles, changes in its abundance may also reflect processes beyond the specific signaling sequence proposed here.

Several links in the model are sensitive to context. Nutrient availability, ROS burden, lysosomal pH, and extracellular acidity can vary together, complicating attribution of an observed effect to any single input. Follow-up studies should therefore measure these conditions directly and test the proposed pathway with more than one perturbation strategy. In particular, TAK1 involvement in p62 phosphorylation should not be equated with proof that TAK1 inhibition will suppress, reverse, or therapeutically improve the broader AMPK–NRF2 response.

Why this cross-domain matters, maturity, and limitations

TAK1 creates a useful experimental bridge between metabolic-stress biology and research on kinase inhibition because the reference study places MAP3K7/TAK1 upstream of p62 phosphorylation in its proposed mechanism. A TAK1 inhibitor could be considered as one way to probe that branch in a follow-up experiment, with appropriate genetic controls and direct pathway readouts. However, the reference study does not report testing (5Z)-7-Oxozeaenol, and its findings do not establish how that compound affects p62, AMPK, NRF2, or tumor growth. This is a mechanistic hypothesis for experimental testing, not a demonstrated transfer of efficacy between metabolic-stress and inflammation models.

Research Support Resources

For follow-up experiments that investigate the TAK1-dependent branch, researchers can use (5Z)-7-Oxozeaenol (SKU B7443) to support similar workflows. It is a TAK1 inhibitor resource for pathway perturbation; its use would need to be validated in the specific cell model and should not be interpreted as a treatment tested in the reference study.